No Data
No Data
Guangxi Wuzhou Zhongheng Group (600252.SH): A holding subsidiary has obtained the supplementary drug application approval notice.
On October 7, Ge Longhui announced that its holding subsidiary Chongqing Lummy Pharmaceutical Co., Ltd. (referred to as "Chongqing Lummy Pharmaceutical") recently received the National Medical Products Administration's approved and issued Cefoperazone sodium for injection (Specification: 50mg) "Supplemental Drug Application Approval Notice".
Guangxi Wuzhou Zhongheng GroupLtd (SHSE:600252) Has Debt But No Earnings; Should You Worry?
Guangxi Wuzhou Zhongheng Group (600252.SH): Intends to transfer part of the subscribed capital contribution of Guohai Zhongheng Fund.
Gelonghui September 25th | Guangxi Wuzhou Zhongheng Group (600252.SH) announced that based on the current business development situation of the company, the company plans to transfer the 90 million yuan subscribed shares and related rights and obligations of Guangxi Wuzhou Zhongheng Fund, which have not been contributed, to the company's related party, Guohai Innovation Capital. Guangxi Wuzhou Zhongheng Fund has entrusted Shenzhen China Enterprise Hua Land Real Estate Assets Evaluation Co., Ltd. to evaluate the value of all equity of the partners of the fund as of June 30, 2024. The assessment value of the paid-in equity of the fund is 101.5555 million yuan, and the assessment value of the unpaid equity is 0 yuan. This transfer involves the unpaid part.
Guangxi Wuzhou Zhongheng Group Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Guangxi Wuzhou Zhongheng Group Co., Ltd.
Guangxi Wuzhou Zhongheng Group (600252.SH) released its performance for the first half of the year, with a net income of 21.9087 million yuan, a decrease of 75.18% year-on-year.
Guangxi Wuzhou Zhongheng Group (600252.SH) released the 2024 interim report, with a revenue of 1...
No Data
No Data